Genentech/Novartis Xolair goes before advisory committee
Asthma treatment Xolair (omalizumab) will go before FDA's Pulmonary-Allergy Drugs Advisory Committee on May 15. Genentech and Novartis are seeking an indication for treatment of moderate-to-severe allergic asthma in adolescents and adults. The firms narrowed the requested indication after FDA deemed the number of patients studied for a younger age group and an allergic rhinitis indication to be insufficient in a July 5, 2001 "complete response" letter. The meeting will be held at the Holiday Inn in Gaithersburg, Md. beginning at 8 a.m. [To watch a 1webcast of this meeting and other meetings, go to FDAAdvisoryCommittee.com]...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.